Skip to main content
OpenTrials
Completed

NCT Number: NCT04529720

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination

In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccines) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy participants aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th;Study ID:TCTR20150703002). A total of 450 participants were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 participants enrolled at each study site. During the study, the participants had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines.

This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of participants who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects).

In this current study, the long-term persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-inactivated Tdap vaccine (Adacel) at 5 years after previously immunized in the TDA202 study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pertussis Bacterial Infections Bacterial Infections and Mycoses Bordetella Infections Gram-Negative Bacterial Infections Infections Respiratory Tract Diseases Respiratory Tract Infections Whooping Cough

Sex eligibility

All sexes

Study type

Observational

Primary location

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi,

Bangkok, 10400, Thailand

About this study

The study population will included all participants who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok.

Participants from all 3 vaccine groups (i.e., participants who had received a single dose of one of the 3 study vaccines (Boostagen®, Pertagen®, or Adacel®) and completed 1-year follow-up visit at Day 336±28 days during the TDA202 study will be called in for informed consent process at Visit 1 at approximately 5 years after vaccination (±56 days) based on Vaccination Date in the TDA202 study. Participants aged ≥18 years who have signed the written Informed Consent Form or participants aged less than 18 years who have co-signed the Informed Consent Form with their parent/legal will be screened for general health status (a survey for medical history, immunization history, history of receiving blood, blood component, immunoglobulin, immunosuppressive drugs or systemic corticosteroid and physical examination) and those who fulfill the pre-defined inclusion criteria and do not meet an exclusion criteria will be enrolled into the study.

Once enrolled, a blood sample (approx. 5 mL) will be taken from all participants. After blood collection, this will be considered as study end for all participants. Participants will be offered a licensed influenza vaccine at the end of Visit 1.

Blood samples collected from all participants who have come back for the 5-year follow-up visit (Visit 1) will be processed for serum preparation. Serum samples will be stored at the laboratory at the study site and will be further shipped to BioNet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against Pertussis Toxin (PT), Filamentous hemagglutinin (FHA), Diphtheria Toxin (DT), and Tetanus Toxin (TT) and PT-neutralizing antibody by Chinese Hamster Ovary (CHO) cells assay) will be performed. ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled participants while CHO cells assay to detect PT-neutralizing antibody will be performed only in the same subset of participants who had been selected for PT-neutralizing antibody study in the initial TDA202 study.

The knowledge from this long-term 5-year antibody persistence study will provide supportive data to identify the best alternative acellular pertussis vaccines to conventional chemically-inactivated vaccines for controlling the resurgence of pertussis disease.

Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A participant will be eligible for inclusion if ALL of the followings apply at the time of screening:

  • Having participated in the initial TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1-year follow-up visit;
  • Written informed consent is obtained for participants aged ≥18 years, or written informed consent are obtained from participants aged <18 years with their parents/legal guardians, co-signed prior to study entry;
  • Healthy, as established by pertinent medical history and physical examination;
  • Capable of complying with study procedures and willing to provide with a blood sample

Exclusion criteria

  • Having received pertussis vaccine since TDA202 study

Treatment and study plan

Biological/Vaccine: Pertagen (aP BioNet)

Biological

Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Biological/Vaccine: Boostagen (TdaP BioNet)

Biological

Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Biological/Vaccine: Adacel

Biological

Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.

The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Primary outcomes

  1. Anti-PT and Anti-FHA GMTs (IU/ml) changed from baseline at 5 Years After Vaccination in All Evaluable Participants by Vaccine Groups

    Time frame: 5 years after vaccination ± 56 days

    Anti-PT and anti-FHA GMTs (IU/mL) at baseline and 5 years after vaccination as assess by ELISA in all evaluable participants by vaccine groups.

  2. Anti-Tetanus and Anti-Diphtheria GMTs (IU/mL) changed from baseline at 5 Years After Vaccination in All Evaluable Participants in Boostagen (BioNet TdaP BioNet) and Adacel Vaccine Groups

    Time frame: 5 years after vaccination ± 56 days

    Anti-Tetanus and anti-Diphtheria GMTs (IU/mL) between baseline and 5 years after vaccination as assessed by ELISA in all evaluable participants in Boostagen (BioNet TdaP BioNet) and Adacel vaccine groups

  3. Seroconversion Rates as Defined by the Proportion of Participants With Booster Response in Anti-PT and Anti-FHA Antibody Titers at Day 28 and 5 Years After Vaccination Compared to Baseline in All Evaluable Participants by Vaccine Groups

    Time frame: 5 years after vaccination ± 56 days

    Booster response:

    • In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL;
    • In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer;
    • In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer

  4. PT Neutralizing GMTs (IU/mL) changed from baseline at 5 Year After Vaccination as Assessed in a Subset of Evaluable Participants by Vaccine Group

    Time frame: 5 years after vaccination ± 56 days

    PT neutralizing GMTs (IU/mL) between baseline and 5 year after vaccination as assessed by PT neutralizing assay in a subset of evaluable participants by vaccine group

  5. Seroconversion Rates Defined by Proportion of Participants With ≥ 4-fold Changed in PT Neutralizing Antibody Titers at Day 28, Day 336 and 5 Years After Vaccination Compared to Baseline in a Subset of Evaluable Participants

    Time frame: Day 28, Day 336 and 5 years after vaccination ± 56 days

    Seroconversion rates as defined by the proportion of participants with ≥ 4-fold increase in PT neutralizing antibody titers at Day 28, Day 336 and 5 years after vaccination compared to baseline as assessed by PT neutralizing assay in a subset of evaluable participants by vaccine group

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Collaborators

  • BioNet-Asia Co., Ltd.

Registry information

Official study title

Antibody Persistence at 5 Years After a Single Dose Vaccination of Acellular Pertussis Vaccines Containing Genetically-inactivated Pertussis Toxin

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Aug 28, 2020
Registry last updated
Jan 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.